Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02ZKR
|
|||
| Former ID |
DNC008301
|
|||
| Drug Name |
BCX-3408
|
|||
| Synonyms |
ULODESINE; 548486-59-5; UNII-JNG8L9460Y; JNG8L9460Y; CHEMBL269864; DADMe-immucillin H; Ulodesine [USAN:INN]; Ulodesine (USAN); DADMe-ImmH,7; 1n3i; AC1L9KNW; 7-[[(3R,4R)-3-(hydroxymethyl)-4-oxidanyl-pyrrolidin-1-ium-1-yl]methyl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one; R-3421; SCHEMBL474735; SCHEMBL16320802; CTK5A2657; BDBM22109; DTXSID00203332; AKOS030554378; DB12353; SB17254; D10431; 4H-Pyrrolo[3,2-d]pyrimidin-4-one,1,5-dihydro-7-[[(3R,4R)-3-hydroxy-4-(hydroxymethyl)-1-pyrrolidinyl]methyl]-; BCX-4208; Ulodesine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Autoimmune diabetes [ICD-11: 5A10] | Phase 2 | [1] | |
| Gout [ICD-11: FA25; ICD-10: M10] | Phase 2 | [1] | ||
| Plaque psoriasis [ICD-11: EA90.0; ICD-10: L40.0] | Phase 2 | [1] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
C12H16N4O3
|
|||
| Canonical SMILES |
C1C(C(CN1CC2=CNC3=C2N=CNC3=O)O)CO
|
|||
| InChI |
1S/C12H16N4O3/c17-5-8-3-16(4-9(8)18)2-7-1-13-11-10(7)14-6-15-12(11)19/h1,6,8-9,13,17-18H,2-5H2,(H,14,15,19)/t8-,9+/m1/s1
|
|||
| InChIKey |
AFNHHLILYQEHKK-BDAKNGLRSA-N
|
|||
| CAS Number |
CAS 548486-59-5
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01407874) A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency. U.S. National Institutes of Health. | |||
| REF 2 | BCX-4208 (RO5092888), a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Is a Novel, Potent Orally Active Anti-T-Cell and B-Cell Agent. 50th ASH Annual Meeting and Exposition. 2008. | |||
| REF 3 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
| REF 4 | Azetidine based transition state analogue inhibitors of N-ribosyl hydrolases and phosphorylases. J Med Chem. 2008 Feb 28;51(4):948-56. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.